Adopted Trials - lymphoma (NHL)
Acronym: R-CODOX M/IVAC
Full Title
A phase II single arm study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) (Age-Adjusted International Prognostic Index (IPI) High or High-Intermediate Risk)
Treatment: simple antibodies (indirect & direct acting)
Phase: II
Chief Investigator: Dr Andrew Mcmillan
Type of trial: Early Phase
Website:
Acronym: R-GCVP
Full Title
A phase II multicentre trial of CVP, rituximan and gemcitabine for the treatment of patients with newly diagnosed diffuse large B-Cell lymphoma considered unsuitable for R-Chop chemotherapy
Treatment: chemotherapy
Phase: II
Chief Investigator: Dr Paul Fields
Type of trial: Early Phase
Website:
Acronym: GEMCITABINE + BEXAROTENE (GemBex)
Full Title
A phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma
Treatment: chemotherapy
Phase: II
Chief Investigator: Prof Tim Illidge
Type of trial: Early Phase
Website:
Acronym: BORTEZOMIB/CHOP
Full Title
A parallel randomised phase II trial of CHOP chemotherapy with or without Bortezomib In Relapsed Mantle Cell Lymphoma
Treatment: chemotherapy
Phase: II
Chief Investigator: Dr S Rule
Type of trial: Early Phase
Website:
Acronym: PACIFICO
Full Title
Phase III multicentre trial comparing two different Purine-Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients (PACIFICO)
Treatment: chemotherapy
Phase: III
Chief Investigator: Andrew Pettitt
Type of trial: Biomarkers
Website:
